Dublin, Nov 16, 2021 (GLOBE NEWSWIRE) – The report “Professional Acne Treatment Market Research Report: By Acne Type, Treatment Type, Professional Type – Global Industry Analysis and demand forecast until 2030 âhas been added to ResearchAndMarkets.com offer.
From $ 6,298.9 million in 2020, the global professional acne treatment market value is expected to reach $ 13,124.5 million by 2030, at a CAGR of 7.6% between 2020 and 2030, according to the market research report.
Main conclusions of this study
Device treatments will quickly become popular in the years to come
Professional treatment sought more frequently for inflammatory acne
A strong drug pipeline, a key driver of market growth
North America’s Largest Market For Professional Acne Treatments
APAC will provide lucrative growth opportunities in the future
Fragmented market due to the presence of many companies
The COVID-19 pandemic has had a negative effect on the professional acne treatment market as nearly all cosmeticians and dermatologists have been forced to lower their shutters, to comply with lockdown protocols. Likewise, companies that produce drugs and devices for the treatment of acne were not operational or functional on a rather small scale, which reduced the supply and trade of the products. On the demand side, people were discouraged from spending on non-essential things as many were under immense financial stress.
The coming years will be characterized by the more rapid growth of the inflammatory bifurcation in the professional acne treatment market, depending on the type of acne. This type of acne is considered more severe than the non-inflammatory type, and it is often painful. Additionally, inflammatory acne cannot be cured by most over-the-counter (OTC) medications, which is why professional intervention is preferred.
In the past, the largest share of the treatment types segment of the professional acne treatment market was held by drug bifurcation. Medicines are readily available, and treatment with them is less complex and expensive than that performed by devices.
Dermatologists are expected to dominate the professional acne treatment market in the near future, under segmentation by type of professional. Compared to cosmeticians, dermatologists have a broader knowledge base and more experience in the treatment of acne, which is why they remain popular among patients.
The market is driven by the following factors:
Increased prevalence of acne: Almost 90% of people on earth, especially young adults and adolescents, suffer from acne at some point in their lives. In addition, the Global Burden of Disease study estimates the incidence in 2019 of this common dermatological problem at 50 million cases in the United States alone.
Adopting a sedentary lifestyle: This is another key driver for the professional acne treatment market as less physical activity leads to increased weight and lipid levels in the body. This, in turn, disrupts hormonal concentration, resulting in an array of skin conditions including hormonal acne.
North America is the largest professional acne treatment market due to increasing prevalence of this disease, increased awareness of new drugs and devices, presence of many other drugs in the pipeline of pharmaceutical companies , such as Johnson & Johnson, Pfizer Inc. and Bausch Health Companies Inc., and the high disposable income of the continent’s population.
The major players in the global professional acne treatment market are Galderma SA, Bausch Health Companies Inc., Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., CHEPLAPHARM Arzneimittel GmbH, Sun Pharmaceutical Industries Ltd., Perrigo Company plc , Bayer AG, Almirall SA, Candela Corporation, Lumenis Ltd., Alma Lasers Ltd., Sciton Inc., Cutera Inc., EL.EN. Spa, Venus Concept Inc., Fotona doo, Erchonia Corporation and InMode Ltd.
Main topics covered:
Chapter 1. Research Context
Chapter 2. Research methodology
Chapter 3. Executive summary
Chapter 4. Presentation
4.1 Definition of market segments
4.1.1 By type of acne
4.1.2 By type of treatment
184.108.40.206.3 Hormonal agents
4.1.3 By type of professional
4.2 Market dynamics
220.127.116.11 Product launches and R&D investments
18.104.22.168 Increase in the number of strategic collaborations
22.214.171.124 Growing adoption of acne treatments
126.96.36.199 Increased prevalence of acne
188.8.131.52 A strong product pipeline
184.108.40.206 Adopting a sedentary lifestyle
4.2.3 Impact Analysis of Engines on Market Forecast
220.127.116.11 Side effects associated with acne medications
18.104.22.168 Availability of alternative treatments
4.2.5 Analysis of the impact of restrictions on market forecasts
22.214.171.124 Huge potential in emerging markets
4.3 Impact of COVID-19
4.4 Comparison of treatments
4.5 Porter’s five forces analysis
4.5.1 Bargaining power of buyers
4.5.2 Bargaining power of suppliers
4.5.3 Intensity of rivalry
4.5.4 Threat of new entrants
4.5.5 Threat of substitutes
4.6 Average duration of acne treatment
4.7 Acne prevalence rate
4.8 Number of dermatologists
4.9 Average price of treatment
Chapter 5. Global Market Size and Forecast
5.1 By type of acne
5.2 By type of treatment
5.2.1 Pharmaceuticals Market, by Type
5.2.2 Devices Market, by Type
5.3 By type of professional
5.4 By region
Chapter 6. North America Market Size and Forecast
Chapter 7. Europe Market Size and Forecast
Chapter 8. APAC Market Size and Forecast
Chapter 9. Railway Lines Market Size and Forecast
Chapter 10. Competitive landscape
10.1 Main offerings of key players
10.2 Recent strategic developments of key players
10.2.1 Product Launches and Approvals
10.2.2 Acquisitions and Mergers
10.2.3 Partnerships and collaborations
10.3 Key Players Market Share Analysis
10.3.1 United States
Chapter 11. Company Profiles
11.1 Galderma SA
11.1.1 Company overview
11.1.2 Product and service offerings
11.2 Johnson & Johnson
11.2.1 Company overview
11.2.2 Product and service offerings
11.2.3 Key financial summary
11.3 Bausch Health Companies Inc.
11.3.1 Company overview
11.3.2 Product and service offerings
11.3.3 Key financial summary
11.4 Pfizer Inc.
11.4.1 Company overview
11.4.2 Product and service offerings
11.4.3 Key financial summary
11.5 CHEPLAPHARM Arzneimittel GmbH
11.5.1 Company overview
11.5.2 Product and service offerings
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Company overview
11.6.2 Product and service offerings
11.6.3 Key Financial Summary
11.7 Sun Pharmaceutical Industries Ltd.
11.7.1 Company overview
11.7.2 Product and service offerings
11.7.3 Key financial summary
11.8 Bayer SA
11.8.1 Company overview
11.8.2 Product and service offerings
11.8.3 Key financial summary
11.9 Perrigo Company plc
11.9.1 Company overview
11.9.2 Product and service offerings
11.9.3 Key financial summary
11.10 Almirall SA
11.10.1 Company overview
11.10.2 Product and service offerings
11.10.3 Key financial summary
11.11 Lumenis Ltd.
11.11.1 Company Overview
11.11.2 Product and service offerings
11.12 Candela Corporation
11.12.1 Company overview
11.12.2 Product and service offerings
11.13 Alma Lasers LtÃ©e
11.13.1 Company Overview
11.13.2 Product and service offerings
11.14 Cutera Inc.
11.14.1 Company overview
11.14.2 Product and service offerings
11.14.3 Key financial summary
11.15 Sciton Inc.
11.15.1 Company Overview
11.15.2 Product and service offerings
11.16 EL.FR. Spa
11.16.1 Company Overview
11.16.2 Product and service offerings
11.16.3 Key financial summary
11.17 Fotona doo
11.17.1 Company Overview
11.17.2 Product and service offerings
11.18 Venus Concept Inc.
11.18.1 Company Overview
11.18.2 Product and service offerings
11.18.3 Key financial summary
11.19 Erchonia Corporation
11.19.1 Company overview
11.19.2 Product and service offerings
11.20 InMode Ltd.
11.20.1 Company overview
11.20.2 Product and service offerings
Chapter 12. Appendix
For more information on this report, visit https://www.researchandmarkets.com/r/dh58cu
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900